

U.S. Vaccines Market By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Others) , By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP) , Polio, Hepatitis, Other Indications) By End User (Pediatric, Adults, Travelers) : Opportunity Analysis and Industry Forecast, 2024-2033

<https://marketpublishers.com/r/UBC594EE7535EN.html>

Date: December 2024

Pages: 90

Price: US\$ 2,177.00 (Single User License)

ID: UBC594EE7535EN

Abstracts

The U.S. vaccines market was valued at \$16.4 billion in 2023, and is projected to reach \$29.1 billion by 2033, growing at a CAGR of 5.9% from 2024 to 2033.

Vaccine is a biological preparation that provides acquired immunity to a particular infectious disease. It contains antigens, which are weakened or inactivated forms of the pathogen, or pieces of the pathogen such as proteins or sugars. When administered, vaccines stimulate the body's immune system to recognize and fight the targeted pathogen, preparing it for future encounters. This proactive approach helps prevent the onset of diseases that can cause significant morbidity and mortality.

Alarming increase in prevalence of infectious diseases, including seasonal flu, influenza, shingles, and pneumonia, has spurred demand for vaccines to prevent outbreaks and mitigate public health risks. According to the Centers for Disease Control and Prevention, seasonal flu infections in the U.S. lead to an average of 140,000 to

710,000 hospitalizations annually, which drives the demand for annual flu vaccines. In addition, U.S. government initiatives, such as the Vaccines for Children program, which provides vaccines at no cost to eligible children, and adult immunization programs, promote access to vaccines, ensuring higher vaccination rates across various population segments and thus driving the market growth. The continuous growth of the vaccine pipeline, with new vaccines targeting diseases like malaria, Zika, and cancer, helps meet unmet medical needs and addresses emerging infectious diseases, further expanding market opportunities. Moreover, the aging U.S. population is significantly augmenting the demand for vaccines like shingles, pneumococcal, and influenza vaccines, as older individuals are more vulnerable to such infections. According to the National Institute on Aging (NIA) in 2020, the U.S. population aged 65 and older is expected to grow from 54 million in 2019 to 94.7 million by 2060. This demographic shift is expected to drive demand for vaccines targeting older adults, including vaccines for shingles and pneumonia. Furthermore, increased awareness and education about the benefits of vaccination, supported by public health campaigns, drive higher vaccination rates and encourage more individuals to get vaccinated against common preventable diseases. However, high costs associated with vaccine research, development, and manufacturing can limit the availability and affordability of vaccines, especially for emerging diseases or smaller market segments. Moreover, public skepticism about vaccine safety, fueled by misinformation and fear, poses a significant barrier to achieving high vaccination rates. On the contrary, breakthroughs in vaccine technology, such as the development of mRNA vaccines, nanoparticle-based vaccines, and adjuvant formulations, contribute to more effective and rapid vaccine production, which are expected to offer remunerative opportunities for the expansion of the market during the forecast period.

The U.S. vaccines market share is segmented on the basis of technology type, indication, and end user. On the basis of technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. Depending on indication, it is classified into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, and rubella; diphtheria, pertussis, and tetanus (DTP); polio; hepatitis; and other indications. By end user, it is segregated into pediatric, adults, and travelers.

Competition Analysis

The major players operating in the U.S. vaccines market include Bavarian Nordic, Merck & Co., Inc., Sanofi, Pfizer, Emergent Biosolutions, CSL, Moderna, Inc., Dynavax Technologies, Novavax, Inc., and GSK Plc. These major players have adopted various

key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines

Additional company profiles with specific to client's interest

Additional country or region analysis- market size and forecast

Expanded list for Company Profiles

Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Technology Type

Inactivated Vaccines

Toxoid Vaccines

Recombinant and Conjugate Vaccines

Live Attenuated Vaccines

Others

By Indication

Pneumococcal Disease

Influenza

Human Papilloma Virus

Meningococcal Disease

Rotavirus

Varicella

Measles, Mumps, and Rubella

Diphtheria, Pertussis, and Tetanus (DTP)

Polio

Hepatitis

Other Indications

By End User

Pediatric

Adults

Travelers

Key Market Players

Bavarian Nordic

Merck & Co., Inc.

Sanofi

Pfizer

Emergent Biosolutions

CSL

Moderna, Inc.

Dynavax Technologies

Novavax, Inc.

GSK plc.

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
 - 1.4.1. Primary Research
 - 1.4.2. Secondary Research
 - 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

- 3.1. Market Definition and Scope
- 3.2. Key Findings
 - 3.2.1. Top Investment Pockets
 - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
 - 3.3.1. Bargaining Power of Suppliers
 - 3.3.2. Threat of New Entrants
 - 3.3.3. Threat of Substitutes
 - 3.3.4. Competitive Rivalry
 - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
 - 3.4.1. Drivers
 - 3.4.2. Restraints
 - 3.4.3. Opportunities

CHAPTER 4: U.S. VACCINES MARKET, BY TECHNOLOGY TYPE

- 4.1. Market Overview
 - 4.1.1 Market Size and Forecast, By Technology Type
- 4.2. Inactivated Vaccines
 - 4.2.1. Key Market Trends, Growth Factors and Opportunities

4.3. Toxoid Vaccines

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.4. Recombinant And Conjugate Vaccines

4.4.1. Key Market Trends, Growth Factors and Opportunities

4.5. Live Attenuated Vaccines

4.5.1. Key Market Trends, Growth Factors and Opportunities

4.6. Others

4.6.1. Key Market Trends, Growth Factors and Opportunities

CHAPTER 5: U.S. VACCINES MARKET, BY INDICATION

5.1. Market Overview

5.1.1 Market Size and Forecast, By Indication

5.2. Pneumococcal Disease

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.3. Influenza

5.3.1. Key Market Trends, Growth Factors and Opportunities

5.4. Human Papilloma Virus

5.4.1. Key Market Trends, Growth Factors and Opportunities

5.5. Meningococcal Disease

5.5.1. Key Market Trends, Growth Factors and Opportunities

5.6. Rotavirus

5.6.1. Key Market Trends, Growth Factors and Opportunities

5.7. Varicella

5.7.1. Key Market Trends, Growth Factors and Opportunities

5.8. Measles, Mumps, And Rubella

5.8.1. Key Market Trends, Growth Factors and Opportunities

5.9. Diphtheria, Pertussis, And Tetanus (DTP)

5.9.1. Key Market Trends, Growth Factors and Opportunities

5.10. Polio

5.10.1. Key Market Trends, Growth Factors and Opportunities

5.11. Hepatitis

5.11.1. Key Market Trends, Growth Factors and Opportunities

5.12. Other Indications

5.12.1. Key Market Trends, Growth Factors and Opportunities

CHAPTER 6: U.S. VACCINES MARKET, BY END USER

6.1. Market Overview

- 6.1.1 Market Size and Forecast, By End User
- 6.2. Pediatric
 - 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.3. Adults
 - 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.4. Travelers
 - 6.4.1. Key Market Trends, Growth Factors and Opportunities

CHAPTER 7: COMPETITIVE LANDSCAPE

- 7.1. Introduction
- 7.2. Top Winning Strategies
- 7.3. Product Mapping Of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top Player Positioning,2023

CHAPTER 8: COMPANY PROFILES

- 8.1. Bavarian Nordic
 - 8.1.1. Company Overview
 - 8.1.2. Key Executives
 - 8.1.3. Company Snapshot
 - 8.1.4. Operating Business Segments
 - 8.1.5. Product Portfolio
 - 8.1.6. Business Performance
 - 8.1.7. Key Strategic Moves and Developments
- 8.2. Merck And Co., Inc.
 - 8.2.1. Company Overview
 - 8.2.2. Key Executives
 - 8.2.3. Company Snapshot
 - 8.2.4. Operating Business Segments
 - 8.2.5. Product Portfolio
 - 8.2.6. Business Performance
 - 8.2.7. Key Strategic Moves and Developments
- 8.3. Sanofi
 - 8.3.1. Company Overview
 - 8.3.2. Key Executives
 - 8.3.3. Company Snapshot

- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
- 8.4. Pfizer
 - 8.4.1. Company Overview
 - 8.4.2. Key Executives
 - 8.4.3. Company Snapshot
 - 8.4.4. Operating Business Segments
 - 8.4.5. Product Portfolio
 - 8.4.6. Business Performance
 - 8.4.7. Key Strategic Moves and Developments
- 8.5. Emergent Biosolutions
 - 8.5.1. Company Overview
 - 8.5.2. Key Executives
 - 8.5.3. Company Snapshot
 - 8.5.4. Operating Business Segments
 - 8.5.5. Product Portfolio
 - 8.5.6. Business Performance
 - 8.5.7. Key Strategic Moves and Developments
- 8.6. CSL
 - 8.6.1. Company Overview
 - 8.6.2. Key Executives
 - 8.6.3. Company Snapshot
 - 8.6.4. Operating Business Segments
 - 8.6.5. Product Portfolio
 - 8.6.6. Business Performance
 - 8.6.7. Key Strategic Moves and Developments
- 8.7. Moderna, Inc.
 - 8.7.1. Company Overview
 - 8.7.2. Key Executives
 - 8.7.3. Company Snapshot
 - 8.7.4. Operating Business Segments
 - 8.7.5. Product Portfolio
 - 8.7.6. Business Performance
 - 8.7.7. Key Strategic Moves and Developments
- 8.8. Dynavax Technologies
 - 8.8.1. Company Overview
 - 8.8.2. Key Executives

- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
- 8.9. Novavax, Inc.
 - 8.9.1. Company Overview
 - 8.9.2. Key Executives
 - 8.9.3. Company Snapshot
 - 8.9.4. Operating Business Segments
 - 8.9.5. Product Portfolio
 - 8.9.6. Business Performance
 - 8.9.7. Key Strategic Moves and Developments
- 8.10. GSK Plc.
 - 8.10.1. Company Overview
 - 8.10.2. Key Executives
 - 8.10.3. Company Snapshot
 - 8.10.4. Operating Business Segments
 - 8.10.5. Product Portfolio
 - 8.10.6. Business Performance
 - 8.10.7. Key Strategic Moves and Developments

LIST OF TABLES

TABLE 1. U.S. VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 (\$BILLION)

TABLE 2. U.S. VACCINES MARKET, BY INDICATION, 2024 - 2033 (\$BILLION)

TABLE 3. U.S. VACCINES MARKET, BY END USER, 2024 - 2033 (\$BILLION)

TABLE 4. BAVARIAN NORDIC: KEY EXECUTIVES

TABLE 5. BAVARIAN NORDIC: COMPANY SNAPSHOT

TABLE 6. BAVARIAN NORDIC: OPERATING SEGMENTS

TABLE 7. BAVARIAN NORDIC: PRODUCT PORTFOLIO

TABLE 8. BAVARIAN NORDIC: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 9. MERCK AND CO., INC.: KEY EXECUTIVES

TABLE 10. MERCK AND CO., INC.: COMPANY SNAPSHOT

TABLE 11. MERCK AND CO., INC.: OPERATING SEGMENTS

TABLE 12. MERCK AND CO., INC.: PRODUCT PORTFOLIO

TABLE 13. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 14. SANOFI: KEY EXECUTIVES

TABLE 15. SANOFI: COMPANY SNAPSHOT

TABLE 16. SANOFI: OPERATING SEGMENTS

TABLE 17. SANOFI: PRODUCT PORTFOLIO

TABLE 18. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 19. PFIZER: KEY EXECUTIVES

TABLE 20. PFIZER: COMPANY SNAPSHOT

TABLE 21. PFIZER: OPERATING SEGMENTS

TABLE 22. PFIZER: PRODUCT PORTFOLIO

TABLE 23. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 24. EMERGENT BIOSOLUTIONS: KEY EXECUTIVES

TABLE 25. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT

TABLE 26. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS

TABLE 27. EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO

TABLE 28. EMERGENT BIOSOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 29. CSL: KEY EXECUTIVES

TABLE 30. CSL: COMPANY SNAPSHOT

TABLE 31. CSL: OPERATING SEGMENTS

TABLE 32. CSL: PRODUCT PORTFOLIO

TABLE 33. CSL: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 34. MODERNA, INC.: KEY EXECUTIVES

TABLE 35. MODERNA, INC.: COMPANY SNAPSHOT

TABLE 36. MODERNA, INC.: OPERATING SEGMENTS

TABLE 37. MODERNA, INC.: PRODUCT PORTFOLIO

TABLE 38. MODERNA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 39. DYNAX TECHNOLOGIES: KEY EXECUTIVES

TABLE 40. DYNAX TECHNOLOGIES: COMPANY SNAPSHOT

TABLE 41. DYNAX TECHNOLOGIES: OPERATING SEGMENTS

TABLE 42. DYNAX TECHNOLOGIES: PRODUCT PORTFOLIO

TABLE 43. DYNAX TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 44. NOVAVAX, INC.: KEY EXECUTIVES

TABLE 45. NOVAVAX, INC.: COMPANY SNAPSHOT

TABLE 46. NOVAVAX, INC.: OPERATING SEGMENTS

TABLE 47. NOVAVAX, INC.: PRODUCT PORTFOLIO

TABLE 48. NOVAVAX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 49. GSK PLC.: KEY EXECUTIVES

TABLE 50. GSK PLC.: COMPANY SNAPSHOT

TABLE 51. GSK PLC.: OPERATING SEGMENTS

TABLE 52. GSK PLC.: PRODUCT PORTFOLIO

TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS**LIST OF FIGURES**

FIGURE 1. U.S. VACCINES MARKET, 2024 - 2033

FIGURE 2. SEGMENTATION OF U.S. VACCINES MARKET, 2024 - 2033

FIGURE 3. TOP INVESTMENT POCKET IN U.S. VACCINES MARKET, 2024 - 2033

FIGURE 4. MODERATE BARGAINING POWER OF BUYERS

FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 6. MODERATE THREAT OF NEW ENTRANTS

FIGURE 7. LOW THREAT OF SUBSTITUTION

FIGURE 8. HIGH COMPETITIVE RIVALRY

FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: U.S. VACCINES MARKET

FIGURE 10. U.S. VACCINES MARKET , BY TECHNOLOGY TYPE, 2024 - 2033 (\$BILLION)

FIGURE 11. U.S. VACCINES MARKET , BY INDICATION, 2024 - 2033 (\$BILLION)

FIGURE 12. U.S. VACCINES MARKET , BY END USER, 2024 - 2033 (\$BILLION)

FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*

FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*

FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*

FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 17. COMPETITIVE DASHBOARD

FIGURE 18. COMPETITIVE HEATMAP: U.S. VACCINES MARKET

FIGURE 19. TOP PLAYER POSITIONING, 2023

FIGURE 20. BAVARIAN NORDIC: NET SALES, 2022-2024 (\$BILLION)

FIGURE 21. BAVARIAN NORDIC: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 22. BAVARIAN NORDIC: REVENUE SHARE, BY REGION, 2024 (%)

FIGURE 23. MERCK AND CO., INC.: NET SALES, 2022-2024 (\$BILLION)

FIGURE 24. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 25. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)

FIGURE 26. SANOFI: NET SALES, 2022-2024 (\$BILLION)

FIGURE 27. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 28. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)

FIGURE 29. PFIZER: NET SALES, 2022-2024 (\$BILLION)

FIGURE 30. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 31. PFIZER: REVENUE SHARE, BY REGION, 2024 (%)

FIGURE 32. EMERGENT BIOSOLUTIONS: NET SALES, 2022-2024 (\$BILLION)

FIGURE 33. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 34. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY REGION, 2024

(%)

FIGURE 35. CSL: NET SALES, 2022-2024 (\$BILLION)

FIGURE 36. CSL: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 37. CSL: REVENUE SHARE, BY REGION, 2024 (%)

FIGURE 38. MODERNA, INC.: NET SALES, 2022-2024 (\$BILLION)

FIGURE 39. MODERNA, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 40. MODERNA, INC.: REVENUE SHARE, BY REGION, 2024 (%)

FIGURE 41. DYNVAVAX TECHNOLOGIES: NET SALES, 2022-2024 (\$BILLION)

FIGURE 42. DYNVAVAX TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2023

(%)

FIGURE 43. DYNVAVAX TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)

FIGURE 44. NOVAVAX, INC.: NET SALES, 2022-2024 (\$BILLION)

FIGURE 45. NOVAVAX, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 46. NOVAVAX, INC.: REVENUE SHARE, BY REGION, 2024 (%)

FIGURE 47. GSK PLC.: NET SALES, 2022-2024 (\$BILLION)

FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2024 (%)

I would like to order

Product name: U.S. Vaccines Market By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Others) , By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP) , Polio, Hepatitis, Other Indications) By End User (Pediatric, Adults, Travelers) : Opportunity Analysis and Industry Forecast, 2024-2033

Product link: <https://marketpublishers.com/r/UBC594EE7535EN.html>

Price: US\$ 2,177.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UBC594EE7535EN.html>